Sweden-headquartered contract development and manufacturing organization Recipharm (STO: RECI-B) has announced an agreement to support formulation and fill-finish a part of the Moderna (Nasdaq: MRNA) COVID-19 vaccine supply outside of the USA.
The activity will be performed in Recipharm’s drug product manufacturing facility located in France.
"This is a material and strategically important agreement for us"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze